The Pentagon Calls Testosterone Testing Readiness—Critics See a Medical Experiment

The Pentagon Calls Testosterone Testing Readiness—Critics See a Medical Experiment
The Pentagon’s new testosterone policy turns a routine military health assessment into a test of how far the armed forces should go to optimize biology—and whether the science can keep pace with the ambition.

Under clinical guidelines effective immediately, active-duty and reserve men aged 30 and older must undergo testosterone blood tests. Younger men generally face testing only if symptoms emerge or they request it, while women will receive symptom-based evaluations for hormonal problems, fatigue and disrupted menstrual cycles. Those diagnosed with low testosterone may receive additional evaluation and, where medically appropriate, voluntary replacement therapy. Non-medical performance enhancement remains prohibited.

The Pentagon and Defense Secretary Pete Hegseth present the program as a force-readiness initiative. Hegseth has said the goal is to ensure troops have “the right testosterone levels to operate at your absolute best,” while the department describes testosterone as a marker linked to strength, bone density, aerobic fitness, mood and cardiovascular health. That argument treats screening as preventive maintenance: identify hormonal problems early, preserve long-term health and sustain combat capability.

The more skeptical interpretation is that the policy moves from treating symptoms to broadly searching for a condition whose military benefits are not established. Medical experts cited in the reporting question whether universal screening will improve readiness and warn that it could encourage unnecessary or potentially harmful treatment.

Both perspectives acknowledge that military life can affect hormone levels. An Army urologist has pointed to operational tempo, chronic stress, blast exposure, traumatic brain injuries and disrupted sleep as possible contributors. The dispute is over what follows: supporters see systematic testing as responsible care; critics see a potentially uneven experiment, particularly because men receive mandatory age-based screening while women are assessed primarily when symptoms appear.